keyword
MENU ▼
Read by QxMD icon Read
search

Tau and PET

keyword
https://www.readbyqxmd.com/read/29136240/postmortem-autopsy-confirmation-of-antemortem-f-18-fddnp-pet-scans-in-a-football-player-with-chronic-traumatic-encephalopathy
#1
Bennet Omalu, Gary W Small, Julian Bailes, Linda M Ercoli, David A Merrill, Koon-Pong Wong, Sung-Cheng Huang, Nagichettiar Satyamurthy, Jennifer L Hammers, John Lee, Robert P Fitzsimmons, Jorge R Barrio
Currently, only presumptive diagnosis of chronic traumatic encephalopathy (CTE) can be made in living patients. We present a modality that may be instrumental to the definitive diagnosis of CTE in living patients based on brain autopsy confirmation of [F-18]FDDNP-PET findings in an American football player with CTE. [F-18]FDDNP-PET imaging was performed 52 mo before the subject's death. Relative distribution volume parametric images and binding values were determined for cortical and subcortical regions of interest...
November 10, 2017: Neurosurgery
https://www.readbyqxmd.com/read/29134465/current-role-for-biomarkers-in-clinical-diagnosis-of-alzheimer-disease-and-frontotemporal-dementia
#2
REVIEW
Nasim Sheikh-Bahaei, Seyed Ahmad Sajjadi, Aimee L Pierce
Purpose of review Alzheimer's disease (AD) and frontotemporal dementia can often be diagnosed accurately with careful clinical history, cognitive testing, neurological examination, and structural brain MRI. However, there are certain circumstances wherein detection of specific biomarkers of neurodegeneration or underlying AD pathology will impact the clinical diagnosis or treatment plan. We will review the currently available biomarkers for AD and frontotemporal dementia (FTD) and discuss their clinical importance...
November 14, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/29128930/prognostic-value-of-amyloid-pet-scan-in-normal-pressure-hydrocephalus
#3
Hyemin Jang, Seong Beom Park, Yeshin Kim, Ko Woon Kim, Jung Il Lee, Sung Tae Kim, Kyung Han Lee, Eun-Suk Kang, Yeong Sim Choe, Sang Won Seo, Hee Jin Kim, Yeo Jin Kim, Cindy W Yoon, Duk L Na
Amyloid positron emission tomography ([18F] florbetaben (FBB) PET) can be used to determine concomitant Alzheimer's disease (AD) in idiopathic normal pressure hydrocephalus (iNPH) patients. FBB PET scans and the tap test were performed in 31 patients with clinically suspected iNPH, and amyloid positive (iNPH/FBB+) and negative (iNPH/FBB-) groups were compared with respect to clinical characteristics. We evaluated prognostic value of FBB PET scans by analyzing the response to the tap test using a linear mixed model...
November 11, 2017: Journal of Neurology
https://www.readbyqxmd.com/read/29126277/-18f-fdg-positron-emission-tomography-in-patients-presenting-with-suspicion-of-giant-cell-arteritis-lessons-from-a-vasculitis-clinic
#4
Stephan Imfeld, Christof Rottenburger, Elke Schegk, Markus Aschwanden, Freimut Juengling, Daniel Staub, Mike Recher, Diego Kyburz, Christoph T Berger, Thomas Daikeler
Aims: The usefulness of [18F] fluorodeoxyglucose-positron emission tomography/computed tomography ([18F]FDG-PET/CT) for diagnosing giant cell arteritis (GCA) has been previously reported. Yet, the interpretation of PET scans is not clear-cut. The present study aimed at determining the best method to analyse PET/CT in a large, real-life cohort of patients presenting with suspicion of GCA. Methods and results: One hundred and three patients with clinical suspicion of GCA undergoing PET/CT between 2006 and 2012 were included...
November 8, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/29124088/considerations-and-code-for-partial-volume-correcting-18-f-av-1451-tau-pet-data
#5
Suzanne L Baker, Anne Maass, William J Jagust
[(18)F]-AV-1451 is a leading tracer used with positron emission tomography (PET) to quantify tau pathology. However, [(18)F]-AV-1451 shows "off target" or non-specific binding, which we define as binding of the tracer in unexpected areas unlikely to harbor aggregated tau based on autopsy literature [1]. Along with caudate, putamen, pallidum and thalamus non-specific binding [2], [3], we have found binding in the superior portion of the cerebellar gray matter, leading us to use inferior cerebellar gray as the reference region...
December 2017: Data in Brief
https://www.readbyqxmd.com/read/29123015/the-irony-of-pet-tau-probe-specificity
#6
Jorge R Barrio
No abstract text is available yet for this article.
November 9, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29114726/concordance-between-different-amyloid-immunoassays-and-visual-amyloid-positron-emission-tomographic-assessment
#7
Shorena Janelidze, Josef Pannee, Alvydas Mikulskis, Ping Chiao, Henrik Zetterberg, Kaj Blennow, Oskar Hansson
Importance: Visual assessment of amyloid positron emission tomographic (PET) images has been approved by regulatory authorities for clinical use. Several immunoassays have been developed to measure β-amyloid (Aβ) 42 in cerebrospinal fluid (CSF). The agreement between CSF Aβ42 measures from different immunoassays and visual PET readings may influence the use of CSF biomarkers and/or amyloid PET assessment in clinical practice and trials. Objective: To determine the concordance between CSF Aβ42 levels measured using 5 different immunoassays and visual amyloid PET analysis...
November 6, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/29114370/taming-alzheimer-s-disease-new-perspectives-newer-horizons
#8
REVIEW
Debraj Sen, Anusree Majumder, Vijinder Arora, Neha Yadu, Ritwik Chakrabarti
Alzheimer's disease (AD) is the leading cause of dementia. However, current therapies do not prevent progression of the disease. New research into the pathogenesis of the disease has brought about a greater understanding of the "amyloid cascade" and associated receptor abnormalities, the role of genetic factors, and revealed that the disease process commences 10 to 20 years prior to the appearance of clinical signs. This greater understanding of the disease has prompted development of novel disease-modifying therapies (DMTs) which may prevent onset or delay progression of the disease...
July 6, 2017: Iranian Journal of Neurology
https://www.readbyqxmd.com/read/29113604/tau-accumulation-in-two-patients-with-frontotemporal-lobe-degeneration-showing-different-types-of-aphasia-using-18f-thk-5351-positron-emission-tomography-a-case-report
#9
Masahiko Takaya, Kazunari Ishii, Chisa Hosokawa, Kazumasa Saigoh, Osamu Shirakawa
Tau deposits in Alzheimer's disease and corticobasal syndrome have been reported using 18F-THK-5351 positron emission tomography (PET). To our knowledge, our study is the first to demonstrate tau deposits in patients with frontotemporal lobe degeneration (FTLD), using 18F-THK-5351 PET. This case report presents two patients, both of whom showed positive Tau deposition using 18F-THK-5351 PET. One patient was diagnosed with semantic variant primary progressive aphasia (PPA) and the other diagnosed with logopenic variant PPA...
November 8, 2017: International Psychogeriatrics
https://www.readbyqxmd.com/read/29105977/tau-pet-imaging-predicts-cognition-in-atypical-variants-of-alzheimer-s-disease
#10
Jeffrey S Phillips, Sandhitsu R Das, Corey T McMillan, David J Irwin, Emily E Roll, Fulvio Da Re, Ilya M Nasrallah, David A Wolk, Murray Grossman
Accumulation of paired helical filament tau contributes to neurodegeneration in Alzheimer's disease (AD). (18) F-flortaucipir is a positron emission tomography (PET) radioligand sensitive to tau in AD, but its clinical utility will depend in part on its ability to predict cognitive symptoms in diverse dementia phenotypes associated with selective, regional uptake. We examined associations between (18) F-flortaucipir and cognition in 14 mildly-impaired patients (12 with cerebrospinal fluid analytes consistent with AD pathology) who had amnestic (n = 5) and non-amnestic AD syndromes, including posterior cortical atrophy (PCA, n = 5) and logopenic-variant primary progressive aphasia (lvPPA, n = 4)...
November 6, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/29093372/-development-of-spect-probes-for-in-vivo-imaging-of-%C3%AE-amyloid-and-tau-aggregates-in-the-alzheimer-s-disease-brain
#11
Hiroyuki Watanabe
 Alzheimer's disease (AD) is the most common form of irreversible dementia among elderly people. In the postmortem brains of AD patients, the deposition of senile plaques composed of β-amyloid (Aβ) peptides and neurofibrillary tangles composed of highly phosphorylated tau proteins are two neuropathological hallmarks. Therefore, the in vivo imaging of Aβ and tau aggregates with positron-emission tomography (PET) or single-photon emission computed tomography (SPECT) would promote drug development, early diagnosis, and monitoring of the disease status in AD patients...
2017: Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan
https://www.readbyqxmd.com/read/29077582/neuroimaging-in-the-diagnosis-of-chronic-traumatic-encephalopathy-a-systematic-review
#12
Philip Sparks, Tim Lawrence, Stephan Hinze
OBJECTIVE: Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repeated subconcussive and concussive head injury. Clinical features include cognitive, behavioral, mood, and motor impairments. Definitive diagnosis is only possible at postmortem. Here, the utility of neuroimaging in the diagnosis of CTE is evaluated by systematically reviewing recent evidence for changes in neuroimaging biomarkers in suspected cases of CTE compared with controls. DATA SOURCES: Providing an update on a previous systematic review of articles published until December 2014, we searched for articles published between December 2014 and July 2016...
October 25, 2017: Clinical Journal of Sport Medicine: Official Journal of the Canadian Academy of Sport Medicine
https://www.readbyqxmd.com/read/29074348/development-of-a-safe-and-scalable-route-towards-a-tau-pet-tracer-precursor
#13
Bjoern Bartels, Philipp Cueni, Dieter Muri, Matthias Koerner
A scalable 5-step synthesis of the diazacarbazole derivative 1 used as tau PET tracer precursor is reported. Key features of this synthesis include a Buchwald-Hartwig amination, a Pd catalyzed CH activation and a Suzuki-Miyaura cross-coupling.
October 12, 2017: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/29071066/the-emerging-role-of-pet-imaging-in-dementia
#14
REVIEW
Leonardo Iaccarino, Arianna Sala, Silvia Paola Caminiti, Daniela Perani
A compelling need in the field of neurodegenerative diseases is the development and validation of biomarkers for early identification and differential diagnosis. The availability of positron emission tomography (PET) neuroimaging tools for the assessment of molecular biology and neuropathology has opened new venues in the diagnostic design and the conduction of new clinical trials. PET techniques, allowing the in vivo assessment of brain function and pathology changes, are increasingly showing great potential in supporting clinical diagnosis also in the early and even preclinical phases of dementia...
2017: F1000Research
https://www.readbyqxmd.com/read/29070667/alzheimer-disease-brain-atrophy-subtypes-are-associated-with-cognition-and-rate-of-decline
#15
Shannon L Risacher, Wesley H Anderson, Arnaud Charil, Peter F Castelluccio, Sergey Shcherbinin, Andrew J Saykin, Adam J Schwarz
OBJECTIVE: To test the hypothesis that cortical and hippocampal volumes, measured in vivo from volumetric MRI (vMRI) scans, could be used to identify variant subtypes of Alzheimer disease (AD) and to prospectively predict the rate of clinical decline. METHODS: Amyloid-positive participants with AD from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 1 and ADNI2 with baseline MRI scans (n = 229) and 2-year clinical follow-up (n = 100) were included. AD subtypes (hippocampal sparing [HpSpMRI], limbic predominant [LPMRI], typical AD [tADMRI]) were defined according to an algorithm analogous to one recently proposed for tau neuropathology...
October 25, 2017: Neurology
https://www.readbyqxmd.com/read/29067322/the-prevalence-and-biomarkers-characteristic-of-rapidly-progressive-alzheimer-s-disease-from-the-alzheimer-s-disease-neuroimaging-initiative-database
#16
Maowen Ba, Xiaofeng Li, Kok Pin Ng, Tharick A Pascoal, Sulantha Mathotaarachchi, Pedro Rosa-Neto, Serge Gauthier
INTRODUCTION: The prevalence and detailed biomarkers' characteristic of rapidly progressive Alzheimer's disease (rpAD) remain incompletely understood. METHODS: A total of 312 mild AD patients from the Alzheimer's Disease Neuroimaging Initiative database were chosen and dichotomized into rpAD and non-rpAD groups. We performed the prevalence and comprehensive biomarker evaluation. RESULTS: The prevalence of rpAD was 17.6% in mild AD. Compared with non-rpAD, there were no differences in APOE ε4/ε4, APOE ε3/ε4, and APOE ε2/ε4 genotype distribution, cerebrospinal fluid tau, phosphorylated tau (p-tau), amyloid-β, hippocampus volume, and amyloid deposition in rpAD...
January 2017: Alzheimer's & Dementia: Translational Research & Clinical Interventions
https://www.readbyqxmd.com/read/29066367/brain-metabolic-correlates-of-csf-tau-protein-in-a-large-cohort-of-alzheimer-s-disease-patients-a-csf-and-fdg-pet-study
#17
Agostino Chiaravalloti, Gaetano Barbagallo, Maria Ricci, Alessandro Martorana, Francesco Ursini, Pasqualina Sannino, Georgios Karalis, Orazio Schillaci
AIMS: physiopathological mechanisms of Alzheimer's disease (AD) are still matter of debate. Especially the role of amyloid β and tau pathology in the development of the disease are still matter of debate. Changes in tau and amyloid β peptide concentration in cerebrospinal fluid (CSF) and hypometabolic patterns at fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET scanning are considered as biomarkers of AD. The present study was aimed to evaluate the relationships between the concentrations of CSF total Tau (t-Tau), phosphorilated Tau (p-Tau) and Aβ1-42 amyloid peptide with (18)F-FDG brain distribution in a group of patients with AD...
October 21, 2017: Brain Research
https://www.readbyqxmd.com/read/29061429/role-of-inflammatory-and-hemostatic-biomarkers-in-alzheimer-s-and-vascular-dementia-a-pilot-study-from-a-tertiary-center-in-northern-india
#18
V Y Vishnu, M Modi, V K Garg, M Mohanty, M K Goyal, V Lal, B R Mittal, S Prabhakar
INTRODUCTION: A reliable plasma biomarker in differentiating between Alzheimer's disease (AD) and Vascular dementia (VaD) is the need of the hour, in most memory clinics. Even though there is no disease modifying treatment, it is important to know the type of dementia for both symptomatic treatment and prognostication. METHODS: Neuropsychological assessment, MRI brain, FDG-PET brain and CSF biomarkers of AD (Aβ42 and total tau) were used for establishing the diagnosis of Mild Cognitive Impairment (MCI), AD or VaD...
October 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/29053874/tau-pathology-and-neurodegeneration-contribute-to-cognitive-impairment-in-alzheimer-s-disease
#19
Alexandre Bejanin, Daniel R Schonhaut, Renaud La Joie, Joel H Kramer, Suzanne L Baker, Natasha Sosa, Nagehan Ayakta, Averill Cantwell, Mustafa Janabi, Mariella Lauriola, James P O'Neil, Maria L Gorno-Tempini, Zachary A Miller, Howard J Rosen, Bruce L Miller, William J Jagust, Gil D Rabinovici
Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau pathology is also intimately associated with neurodegeneration and amyloid pathology. The aim of the present study was therefore to assess whether grey matter atrophy and amyloid pathology contribute to the relationship between tau pathology, as measured with 18F-AV-1451-PET imaging, and cognitive deficits in Alzheimer's disease. We included 40 amyloid-positive patients meeting criteria for mild cognitive impairment due to Alzheimer's disease (n = 5) or probable Alzheimer's disease dementia (n = 35)...
October 7, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/29050382/distinct-18f-av-1451-tau-pet-retention-patterns-in-early-and-late-onset-alzheimer-s-disease
#20
Michael Schöll, Rik Ossenkoppele, Olof Strandberg, Sebastian Palmqvist, Jonas Jögi, Tomas Ohlsson, Ruben Smith, Oskar Hansson
Patients with Alzheimer's disease can present with different clinical phenotypes. Individuals with late-onset Alzheimer's disease (>65 years) typically present with medial temporal lobe neurodegeneration and predominantly amnestic symptomatology, while patients with early-onset Alzheimer's disease (<65 years) exhibit greater neocortical involvement associated with a clinical presentation including dyspraxia, executive dysfunction, or visuospatial impairment. We recruited 20 patients with early-onset Alzheimer's disease, 21 with late-onset Alzheimer's disease, three with prodromal early-onset Alzheimer's disease and 13 with prodromal late-onset Alzheimer's disease, as well as 30 cognitively healthy elderly controls, that had undergone 18F-AV-1451 tau positron emission tomography and structural magnetic resonance imaging to explore whether early- and late-onset Alzheimer's disease exhibit differential regional tau pathology and atrophy patterns...
September 1, 2017: Brain: a Journal of Neurology
keyword
keyword
114281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"